PTC Therapeutics, Inc.
PTCTNASDAQHealthcare● Active
$69.89
$-1.08(-1.53%)
Market Cap$5.8B
P/E Ratio—
52W High$87.5
52W Low$43.175
PTC Therapeutics, Inc. (PTCT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PTCT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.03
Est. -$0.45 · +93.3%
Revenue
$0.27B
Est. $0.22B · +25.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
PTCT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.28 | — | — | — | $0.29B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.45 | -$0.03 | +93.3% | $0.27B | $0.22B | +25.4% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -$0.21 | -$1.67 | -695.2% | $0.16B | $0.28B | -41.1% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$1.19 | $0.20 | +116.8% | $0.21B | $0.28B | -25.0% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.07 | -$0.83 | +22.4% | $0.18B | $0.19B | -6.6% |
| ▲ Q2 FY2025 | May 6, 2025 | -$1.08 | $10.04 | +1029.6% | $1.18B | $0.37B | +215.6% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$1.12 | -$0.24 | +78.6% | $0.21B | $0.25B | -14.4% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$1.54 | -$1.39 | +9.7% | $0.20B | $0.19B | +3.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.03
EPS Est.
-$0.45
EPS Surpr.
+93.3%
Revenue
$0.27B
Q1 FY2026
Feb 19, 2026Miss
EPS Actual
-$1.67
EPS Est.
-$0.21
EPS Surpr.
-695.2%
Revenue
$0.16B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.20
EPS Est.
-$1.19
EPS Surpr.
+116.8%
Revenue
$0.21B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.83
EPS Est.
-$1.07
EPS Surpr.
+22.4%
Revenue
$0.18B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$10.04
EPS Est.
-$1.08
EPS Surpr.
+1029.6%
Revenue
$1.18B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$1.12
EPS Surpr.
+78.6%
Revenue
$0.21B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$1.39
EPS Est.
-$1.54
EPS Surpr.
+9.7%
Revenue
$0.20B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.18 | $0.21 | $0.23 | 2 |
| Q3 FY2027 | $0.23 | $0.28 | $0.30 | 1 |
| Q2 FY2027 | $0.07 | $0.08 | $0.09 | 1 |
| Q1 FY2027 | $0.09 | $0.10 | $0.11 | 2 |
| Q4 FY2026 | $0.10 | $0.12 | $0.13 | 2 |
| Q3 FY2026 | $-0.12 | $0.25 | $0.41 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.4B | 3 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 4 |
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 4 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +93.3% | $66.57 | $64.49 | -3.12% |
| ▼ Q1 FY2026 | Feb 19, 2026 | -695.2% | $68.93 | $69.90 | +1.41% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +116.8% | $67.93 | $67.72 | -0.31% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +22.4% | $51.36 | $50.36 | -1.95% |
| ▲ Q2 FY2025 | May 6, 2025 | +1029.6% | $40.65 | $36.19 | -10.97% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +78.6% | $50.96 | $50.57 | -0.77% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +9.7% | $43.18 | $42.96 | -0.51% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -16.0% | $31.85 | $32.45 | +1.88% |
Q2 FY2026-3.12%
Report Date
May 7, 2026
EPS Beat/Miss
+93.3%
Price Before
$66.57
Price After
$64.49
Q1 FY2026+1.41%
Report Date
Feb 19, 2026
EPS Beat/Miss
-695.2%
Price Before
$68.93
Price After
$69.90
Q4 FY2025-0.31%
Report Date
Nov 4, 2025
EPS Beat/Miss
+116.8%
Price Before
$67.93
Price After
$67.72
Q3 FY2025-1.95%
Report Date
Aug 7, 2025
EPS Beat/Miss
+22.4%
Price Before
$51.36
Price After
$50.36
Q2 FY2025-10.97%
Report Date
May 6, 2025
EPS Beat/Miss
+1029.6%
Price Before
$40.65
Price After
$36.19
Q1 FY2025-0.77%
Report Date
Feb 27, 2025
EPS Beat/Miss
+78.6%
Price Before
$50.96
Price After
$50.57
Q4 FY2024-0.51%
Report Date
Nov 7, 2024
EPS Beat/Miss
+9.7%
Price Before
$43.18
Price After
$42.96
Q3 FY2024+1.88%
Report Date
Aug 8, 2024
EPS Beat/Miss
-16.0%
Price Before
$31.85
Price After
$32.45
Avg Beat Reaction-2.94%
Avg Miss Reaction+1.65%
Beat Rate6 / 8 quarters
Largest Move-10.97% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PTCT ends December
PTC Therapeutics, Inc. (PTCT) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.03 — beating the analyst consensus of $-0.45 by +93.3%. The next PTCT earnings date is expected around September 1, 2026.
Each quarter, investors track PTCT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PTCT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PTCT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PTCT earnings · 5 questionsPTC Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. PTCT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PTCT historically reports after market close (AMC).
PTCT earnings datewhen is PTCT earningsPTCT next earnings datewhen does PTCT report earningsPTCT earnings calendar
▸ Source: FMP · PTC Therapeutics, Inc. SEC filings · US GAAP · PTC Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026